• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

Markets tumble worldwide as Fed resets expectations: $400 billion wiped off SpaceX stock

2

After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup

3

Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'

1

Markets tumble worldwide as Fed resets expectations: $400 billion wiped off SpaceX stock

2

After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup

3

Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'
C-SuitePharmaceutical Industry

The CEO who loves AI autodidacts — and desperately needs his experts

Nick Lichtenberg
By
Nick Lichtenberg
Nick Lichtenberg
Business Editor
Down Arrow Button Icon
Nick Lichtenberg
By
Nick Lichtenberg
Nick Lichtenberg
Business Editor
Down Arrow Button Icon
June 3, 2026, 9:00 AM ET
bb
Amgen CEO Robert "Bob" Bradway.courtesy of Amgen
Add Fortune on Google for similar content.

Bob Bradway has a word for the kind of leader who will thrive in the AI era: “autodidact.” Curious. Self-taught. Comfortable with uncertainty. The kind of person who picks up a new tool on a Saturday and figures it out by Sunday — which, as it happens, is exactly what Bradway himself does.

Recommended Video

The Amgen CEO spends his weekends vibe-coding, has required his entire senior executive team to take AI courses, and talks about artificial intelligence with a rare fluency. In a podcast interview with AI pioneer Andrew Ng, he was told: “A lot of times you sound more like an AI person than a biotech CEO.”

The irony is that Bradway runs a company built on the opposite of the autodidact. Amgen’s competitive moat is its experts — scientists who have spent decades learning that molecules are delicate constructions indeed. “The hallways are full of people who have the experience of understanding if you make a substitution of one amino acid for another, there’s a consequence,” Bradway said. “We want to be very careful not to lose that.”

Reconciling those two things — the adaptable generalist and the irreplaceable specialist — is the central challenge of Bradway’s AI moment. And few CEOs are better positioned to navigate it. That’s because Bradway didn’t just start thinking about AI recently. He started in 2012.

That year, Amgen acquired DeCODE Genetics, a small Icelandic company holding longitudinal genomic data on virtually the entire population of Iceland — not a drug or a patent, but a bet that data and AI would eventually transform how medicines get discovered. His peers were skeptical. Even Andrew Ng, who would later become a close collaborator, told Bradway at the time that the genetic data wasn’t “tractable” yet and steered him toward nearer-term AI applications like computer vision. Bradway made both bets and today, an Nvidia SuperPod hums in Reykjavik, Amgen has developed its own protein folding models, and the company is actively pursuing zero-shot antibody design — using AI to engineer drug molecules without prior experimental examples.

The results are tangible, Bradway said. Amgen is now selecting drug candidates for clinical development roughly 50% faster than before. Rather than relying solely on DeepMind’s celebrated AlphaFold, Bradway pushed his team to look past the hype and identify precisely what the model could and couldn’t do for their specific needs — then build on top of it. “We’re not relying on any single approach,” he said.

Amgen told Fortune that it has several “tangible examples” of how AI is additive and supportive to its teams’ work, with a focus on freeing up time for them to focus on what really moves the needle in terms of getting medicines to patients. It has reduced production line clearance time at one manufacturing site from approximately 30 minutes to about two minutes per batch run, and in certain trials, participants were enrolled up to three times more efficiently, according to the company. AI tools and training available companywide include Microsoft Copilot and OpenAI’s ChatGPT Enterprise, alongside investments in training education and responsible-use frameworks. 

His next frontier is agentic AI, and the timeline is explicit: “2026 is the year we all need to figure out what agentic AI is.” The opportunity, as he described it, is profound: scientists today burn hours filling out forms, requisitioning materials, summarizing data — work that agentic systems could absorb entirely, freeing researchers to do what only they can do. “That’s magic,” he said. It’s also where the autodidact-versus-expert tension gets resolved, in Bradway’s telling: AI is liberating, rather than displacing. “Hopefully they have more time to use the essence of their skill,” he said, “and less time devoted to menial things.”

Whether that reassurance lands with employees is another matter. Bradway acknowledged that America broadly doesn’t trust AI and that uncertainty breeds anxiety. “There is a lot of misinformation and there’s a lot of uncertainty and humans hate the unknown, right? Humans don’t like to be kept in the dark and so the more we can share transparently what we’re doing, I think the better.” Still, he admitted, “I don’t have the answer to that, although as you can see, I’m an optimist.”

He’s also, at this point, a proven one. While other CEOs are still debating AI’s return on investment, Bradway is openly baffled by the hand-wringing. “I read a lot and hear a lot about people expressing frustration that they’re not earning a return from the investments that they’re making. I’m a little bit puzzled by that,” he said. Then again, he noted that in biotech, patience isn’t optional and a single molecule can consume a decade-and-a-half, so maybe his “bewilderment” is down to the different calculus. The companies that can’t tolerate uncertainty, he implied, may be precisely the ones that fall behind.

Historically, the process with molecules has relied heavily on iterative laboratory work, manual data review and sequential testing, and AI can help researchers analyze significantly larger datasets, model molecular behavior, predict protein structures, and evaluate candidate molecules earlier in the process. The goal, Amgen said, is to deprioritize less promising candidates earlier. 

“Being late to this party is going to be expensive,” he said. “Being early to the party has the potential for real benefit.”

For this story, Fortune journalists used generative AI as a research tool. An editor verified the accuracy of the information before publishing.

Subscribe to Fortune Gulf Brief. Every Tuesday, this new newsletter delivers clear-eyed, authoritative intelligence on the deals, decisions, policies, and power shifts shaping one of the world’s most consequential regions, written for the people who need to act on it. Sign up here.
About the Author
Nick Lichtenberg
By Nick LichtenbergBusiness Editor
LinkedIn icon

Nick Lichtenberg is business editor and was formerly Fortune's executive editor of global news.

See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in C-Suite

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in C-Suite

vimal
Energyenergy prices
Honeywell CEO: America can lead the energy era defined by AI and hyper-demand — if policy moves fast enough
By Vimal KapurJune 23, 2026
14 hours ago
rp
CommentaryLaw
Cooley CEO: Big Law won’t survive if it treats AI as just an efficiency tool
By Rachel ProffittJune 23, 2026
16 hours ago
Saudi Aramco’s chairman calls for “energy realism” 
Middle EastInvestment
Saudi Aramco’s chairman calls for “energy realism” 
By Melissa HancockJune 23, 2026
17 hours ago
‘This is the least crazy AI is ever going to be’: The lessons Europe’s execs must take from Anthropic’s shutdown
AIAnthropic
‘This is the least crazy AI is ever going to be’: The lessons Europe’s execs must take from Anthropic’s shutdown
By Sam BirchallJune 23, 2026
18 hours ago
jalen
CommentaryLeadership
What leaders can learn from the Knicks ending their 53-year championship drought
By Melissa Dawn SimkinsJune 22, 2026
1 day ago
Sony industry starmaker Clive Davis, who launched the careers of Janis Joplin and Whitney Houston, dead at 94
Arts & EntertainmentMusic
Sony industry starmaker Clive Davis, who launched the careers of Janis Joplin and Whitney Houston, dead at 94
By The Associated Press, Mark Sherman and NEKESA MUMBI MOODYJune 22, 2026
1 day ago

Most Popular

Markets tumble worldwide as Fed resets expectations: $400 billion wiped off SpaceX stock
Banking
Markets tumble worldwide as Fed resets expectations: $400 billion wiped off SpaceX stock
By Jim EdwardsJune 23, 2026
17 hours ago
After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup
Success
After forcing workers back to the office, Goldman Sachs and JPMorgan Chase are now letting their staff work remotely—but only for the World Cup
By Orianna Rosa RoyleJune 23, 2026
14 hours ago
Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'
Success
Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'
By Sydney LakeJune 21, 2026
3 days ago
Current price of oil as of June 22, 2026
Personal Finance
Current price of oil as of June 22, 2026
By Joseph HostetlerJune 22, 2026
2 days ago
Meet the 2 men putting New York's $300 billion pension fund in play for the first time in 20 years
Investing
Meet the 2 men putting New York's $300 billion pension fund in play for the first time in 20 years
By Nick LichtenbergJune 22, 2026
1 day ago
By 7 a.m., Bank of America’s CEO has already read 5 newspapers, his email inbox, and hit the gym—he says if you’re late to meetings, you’re ‘selfish’
Success
By 7 a.m., Bank of America’s CEO has already read 5 newspapers, his email inbox, and hit the gym—he says if you’re late to meetings, you’re ‘selfish’
By Preston ForeJune 22, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.